What the EU HTA Regulation Means for Biotechs in 2025 and Beyond
Europe has raised the bar on clinical assessment for market access. In January 2025, the EU began the first phase of implementation, creating a more structured and predictable approach to clinical assessment. For biotechs, this marks a structural shift with direct and measurable consequences for how evidence supports patient access. This EU HTA Regulation timeline makes the shift concrete bringing earlier evidence decisions forward and tightening execution windows. It also creates a clearer opportunity to plan evidence earlier, rather than react under deadline.
For nearly two decades, Europe has struggled with a systemic mismatch providing a single regulatory approval, but with 27 different national HTA systems to tackle, each with its own expectations, comparators, timelines, and evidentiary preferences. A therapy approved on the same day across the EU can still face different reimbursement outcomes.
These differences have historically made access planning more complex, often requiring sponsors to navigate multiple evidence expectations in parallel. The new HTA Regulation aims to change this. As with any major reform, most of the transition work will sit with the companies developing the medicines.
In brief:The EU HTA Regulation introduces a mandatory Joint Clinical Assessment (JCA) that shifts Europe toward a shared clinical evaluation and raises expectations for demonstrating relative clinical effectiveness. For biotechs, the implication is practical: decisions about comparators, endpoints, and evidence strategy need to happen earlier, and teams may have limited time to assemble a complete dossier once PICO scoping is set. Planning late turns JCA into damage control.
A Shift Toward a Shared Clinical Standard
At the center of the regulation is the Joint Clinical Assessment (JCA). It centralises the evaluation of clinical effectiveness and safety into one EU-level process rather than 27 national processes.
- 2025: oncology + ATMPs
- 2028: orphan drugs
- 2030: all centrally authorised medicines
The model appears straightforward. However, its operational requirements raise the evidentiary bar for evaluation and access.
The JCA is built on the principle that Europe should not just know that a therapy works, but how well it works compared to what patients are currently receiving in everyday clinical practice. That means developers must demonstrate not only a positive benefit–risk balance for their therapy (EMA’s focus) but also its relative value within the evolving European treatment landscape.
For companies coming from a US-first development mindset, this shift often lands as a surprise. FDA alignment isn’t enough. A trial designed for regulatory efficiency may offer little of what HTA assessors need. And once the JCA procedure starts, timelines leave no room for improvisation.
A Fast-Moving System with Non-Negotiable Timelines
When a company submits its Marketing Authorization Application (MAA) and the EMA validates it, the JCA clock starts ticking. HTA assessors define the assessment scope in the format of the PICO framework, specifying the population, intervention, comparators, and outcomes they expect to see addressed. From the moment the PICO lands in your inbox, you have 100 days to produce a fully aligned JCA dossier. For new indications and accelerated pathways, that window is even shorter.
In practice, very little new data – if any – can be generated in such a short time frame. Without early HTA alignment, the JCA phase is reduced to damage control.
Why This Matters So Much for Biotechs
This regulation touches nearly every aspect of development, and the effects are immediate. JCA is now a required part of the European access pathway.
For oncology and rare disease developers, the evidence base is inherently constrained. These programs rely on small populations, surrogate endpoints, and sometimes single-arm trials —designs that support regulatory approval but don’t always translate into the comparative evidence needed for HTA. ATMPs face an additional challenge: immature durability data, limited long-term follow-up, and a scarcity of natural history comparators.
In all of these cases, the question isn’t simply: Does the therapy work?
It’s: Does it work better than the right alternatives? And do we have the evidence to prove it?
This relative effectiveness assessment is where the JCA creates pressure. The JCA comparators aren’t chosen by the company. They’re chosen by assessors based on real clinical practice which vary significantly across Europe. A single label may split into multiple PICOs because treatment pathways diverge across markets.
Without anticipating these nuances early, teams risk facing evidence gaps when it’s too late to address them.
How to Move with Confidence Under the New System
The JCA requires a change in orientation: clinical evidence must be planned earlier and integrated across functions. Trial design ideally reflects both the regulatory requirements and the HTA reality as far as possible. Market access must engage earlier than ever before, long before pivotal readouts.
When we partner with biotechs, we work to ensure that HTA considerations are built into development from the start. We support companies in mapping plausible PICOs, assessing comparator expectations across key EU markets, preparing evidence generation strategies, and building internal governance for parallel MAA + JCA submissions.
And more importantly, we help teams see around corners — from comparators that may not hold, endpoints unlikely to meet HTA preferences, and the analyses that will be required later.
Because the stakes go beyond approval. They include access, time to market, patient reach, and the strength of the value narrative required to navigate 27 national contexts.
We also help teams prioritise under constraint. JCA expands evidence expectations, but biotech resources are finite, and misallocated effort can quietly undermine future value. We work with companies to focus on the evidence choices that will have the greatest downstream impact on HTA outcomes and national decision-making, rather than dispersing effort across low-value activities. Getting these priorities right early can be the difference between a JCA opinion that enables access, and one that creates friction later.
The Bottom Line
The new HTA Regulation cannot be treated as an afterthought. It calls for a shift in approach — one that weighs relative effect alongside absolute effect, anticipates evidence needs early, and brings clinical, regulatory, and access planning together well before submission.
For biotechs preparing to launch in Europe, the issue is not whether the HTA reform will affect you – because it certainly will, but how early you choose to prepare for it.
The answer: start preparing now.
Related reading
Explore the guide: EU HTA Regulation guide
Continue reading: JCA 100-day timeline
